# Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

> **NCT06963346** · PHASE1 · SUSPENDED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 12 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06963346
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-06-24
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 12 (ESTIMATED)
- **Why stopped:** Slow Accrual
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963346, "Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06963346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*